{
  "address1": "1 North Waukegan Road",
  "city": "North Chicago",
  "state": "IL",
  "zip": "60064-6400",
  "country": "United States",
  "phone": "847 932 7900",
  "website": "https://www.abbvie.com",
  "industry": "Drug Manufacturers\u2014General",
  "industryDisp": "Drug Manufacturers\u2014General",
  "sector": "Healthcare",
  "sectorDisp": "Healthcare",
  "longBusinessSummary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Beh\u00e7et's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.",
  "fullTimeEmployees": 50000,
  "companyOfficers": [
    {
      "maxAge": 1,
      "name": "Mr. Richard A. Gonzalez",
      "age": 68,
      "title": "Chairman & CEO",
      "yearBorn": 1954,
      "fiscalYear": 2022,
      "totalPay": 6948244,
      "exercisedValue": 0,
      "unexercisedValue": 43528872
    },
    {
      "maxAge": 1,
      "name": "Mr. Robert A. Michael",
      "age": 52,
      "title": "Pres & COO",
      "yearBorn": 1970,
      "fiscalYear": 2022,
      "totalPay": 3998042,
      "exercisedValue": 0,
      "unexercisedValue": 13150419
    },
    {
      "maxAge": 1,
      "name": "Mr. Scott T. Reents",
      "age": 54,
      "title": "Exec. VP & CFO",
      "yearBorn": 1968,
      "fiscalYear": 2022,
      "totalPay": 2972736,
      "exercisedValue": 0,
      "unexercisedValue": 5172329
    },
    {
      "maxAge": 1,
      "name": "Dr. Azita  Saleki-Gerhardt Ph.D.",
      "age": 59,
      "title": "Exec. VP & COO",
      "yearBorn": 1963,
      "fiscalYear": 2022,
      "totalPay": 2576755,
      "exercisedValue": 0,
      "unexercisedValue": 28534760
    },
    {
      "maxAge": 1,
      "name": "Mr. Jeffrey Ryan Stewart",
      "age": 53,
      "title": "Exec. VP & Chief Commercial Officer",
      "yearBorn": 1969,
      "fiscalYear": 2022,
      "totalPay": 2983231,
      "exercisedValue": 2777988,
      "unexercisedValue": 10864175
    },
    {
      "maxAge": 1,
      "name": "Dr. Thomas J. Hudson M.D.",
      "age": 60,
      "title": "Sr. VP of R&D and Chief Scientific Officer",
      "yearBorn": 1962,
      "exercisedValue": 0,
      "unexercisedValue": 0
    },
    {
      "maxAge": 1,
      "name": "Ms. Elizabeth  Shea",
      "title": "VP of Investor Relations",
      "exercisedValue": 0,
      "unexercisedValue": 0
    },
    {
      "maxAge": 1,
      "name": "Ms. Tracie  Haas",
      "title": "Sr. VP of Corp. Responsibility, Brand & Communications",
      "exercisedValue": 0,
      "unexercisedValue": 0
    },
    {
      "maxAge": 1,
      "name": "Mr. Timothy J. Richmond",
      "age": 56,
      "title": "Exec. VP & Chief HR Officer",
      "yearBorn": 1966,
      "fiscalYear": 2013,
      "exercisedValue": 0,
      "unexercisedValue": 0
    },
    {
      "maxAge": 1,
      "name": "Dr. Nicholas R. Donoghoe M.D.",
      "age": 41,
      "title": "Exec. VP and Chief Bus. & Strategy Officer",
      "yearBorn": 1981,
      "exercisedValue": 0,
      "unexercisedValue": 0
    }
  ],
  "auditRisk": 9,
  "boardRisk": 7,
  "compensationRisk": 7,
  "shareHolderRightsRisk": 9,
  "overallRisk": 9,
  "governanceEpochDate": 1693526400,
  "compensationAsOfEpochDate": 1672444800,
  "maxAge": 86400,
  "priceHint": 2,
  "previousClose": 153.43,
  "open": 153.9,
  "dayLow": 152.53,
  "dayHigh": 153.825,
  "regularMarketPreviousClose": 153.43,
  "regularMarketOpen": 153.9,
  "regularMarketDayLow": 152.53,
  "regularMarketDayHigh": 153.825,
  "dividendRate": 5.92,
  "dividendYield": 0.038599998,
  "exDividendDate": 1697068800,
  "payoutRatio": 1.1893001,
  "fiveYearAvgDividendYield": 4.49,
  "beta": 0.547026,
  "trailingPE": 31.427984,
  "forwardPE": 13.747975,
  "volume": 3048722,
  "regularMarketVolume": 3048722,
  "averageVolume": 4934364,
  "averageVolume10days": 4371070,
  "averageDailyVolume10Day": 4371070,
  "bid": 152.74,
  "ask": 153.6,
  "bidSize": 800,
  "askSize": 900,
  "marketCap": 269593739264,
  "fiftyTwoWeekLow": 130.96,
  "fiftyTwoWeekHigh": 168.11,
  "priceToSalesTrailing12Months": 4.8121977,
  "fiftyDayAverage": 147.6478,
  "twoHundredDayAverage": 150.0206,
  "trailingAnnualDividendRate": 5.85,
  "trailingAnnualDividendYield": 0.038128138,
  "currency": "USD",
  "enterpriseValue": 323470098432,
  "profitMargins": 0.15502,
  "floatShares": 1762275557,
  "sharesOutstanding": 1765049984,
  "sharesShort": 12454309,
  "sharesShortPriorMonth": 11436751,
  "sharesShortPreviousMonthDate": 1690761600,
  "dateShortInterest": 1693440000,
  "sharesPercentSharesOut": 0.0070999996,
  "heldPercentInsiders": 0.00131,
  "heldPercentInstitutions": 0.71415,
  "shortRatio": 3.02,
  "shortPercentOfFloat": 0.0070999996,
  "impliedSharesOutstanding": 1765049984,
  "bookValue": 7.29,
  "priceToBook": 20.95199,
  "lastFiscalYearEnd": 1672444800,
  "nextFiscalYearEnd": 1703980800,
  "mostRecentQuarter": 1688083200,
  "earningsQuarterlyGrowth": 1.19,
  "netIncomeToCommon": 8634999808,
  "trailingEps": 4.86,
  "forwardEps": 11.11,
  "pegRatio": -3.12,
  "enterpriseToRevenue": 5.774,
  "enterpriseToEbitda": 11.079,
  "52WeekChange": 0.08653784,
  "SandP52WeekChange": 0.18466556,
  "lastDividendValue": 1.48,
  "lastDividendDate": 1689206400,
  "exchange": "NYQ",
  "quoteType": "EQUITY",
  "symbol": "ABBV",
  "underlyingSymbol": "ABBV",
  "shortName": "AbbVie Inc.",
  "longName": "AbbVie Inc.",
  "firstTradeDateEpochUtc": 1357137000,
  "timeZoneFullName": "America/New_York",
  "timeZoneShortName": "EDT",
  "uuid": "73238d42-cdcc-3f92-8141-dd675addae10",
  "messageBoardId": "finmb_141885706",
  "gmtOffSetMilliseconds": -14400000,
  "currentPrice": 152.74,
  "targetHighPrice": 205.0,
  "targetLowPrice": 135.0,
  "targetMeanPrice": 169.61,
  "targetMedianPrice": 168.0,
  "recommendationMean": 2.4,
  "recommendationKey": "buy",
  "numberOfAnalystOpinions": 23,
  "totalCash": 8766000128,
  "totalCashPerShare": 4.966,
  "ebitda": 29195999232,
  "totalDebt": 61392998400,
  "quickRatio": 0.628,
  "currentRatio": 0.895,
  "totalRevenue": 56022999040,
  "debtToEquity": 475.988,
  "revenuePerShare": 31.651,
  "returnOnAssets": 0.09175,
  "returnOnEquity": 0.63017,
  "grossProfits": 41527000000,
  "freeCashflow": 23683999744,
  "operatingCashflow": 25542000640,
  "earningsGrowth": 1.234,
  "revenueGrowth": -0.049,
  "grossMargins": 0.70473,
  "ebitdaMargins": 0.52114,
  "operatingMargins": 0.36498,
  "financialCurrency": "USD",
  "trailingPegRatio": 6.0893
}